Pharmacologic therapy of atrial flutter

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Atrial flutter is an important arrhythmia characterized by right atrial macroreentry.
• Current drug therapies have limited efficacy for acute termination of atrial flutter.

Purpose of the Study:

• To review the treatment strategies for atrial flutter, including pharmacologic agents, pacing, and radiofrequency ablation.
• To discuss the risks associated with atrial flutter treatment, such as 1:1 atrioventricular conduction.
• To highlight the uncertainties regarding thromboembolic risk and prophylactic anticoagulation in atrial flutter.

Main Methods:

• Review of existing literature on atrial flutter mechanisms, treatments, and associated risks.
• Analysis of the efficacy and limitations of various antiarrhythmic drugs and pacing strategies.
• Discussion of the role of radiofrequency ablation and the current understanding of thromboembolic risks.

Main Results:

• Pacing combined with drug therapy significantly improves the success rate of restoring sinus rhythm compared to drugs alone.
• Several antiarrhythmic agents are useful, but definitive efficacy studies are lacking.
• AV nodal blocking drugs may protect against 1:1 AV conduction, but their efficacy and prevalence of this effect require further study.
• Radiofrequency ablation is a viable option when drug management is ineffective.

Conclusions:

• Atrial flutter management involves a combination of antiarrhythmic drugs, pacing, and potentially radiofrequency ablation.
• Significant questions remain regarding the risk of 1:1 conduction, the efficacy of AV nodal blockade, and the necessity of prophylactic anticoagulation.
• Further research is needed to address these clinical uncertainties and optimize patient care for atrial flutter.